Long-term use of proton pump inhibitors does not affect the frequency, growth, or histologic characteristics of colon adenomas

Alimentary Pharmacology and Therapeutics

Volumn 26, Issue 7, 2007, Pages 1051-1061

  Singh, M ^b   Dhindsa, G ^b   Friedland, S ^a,b   Triadafilopoulos, G ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR;

ADENOMATOUS POLYP; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RISK; CANCER SIZE; COLON POLYP; COLONOSCOPY; CONTROLLED STUDY; DEMOGRAPHY; ETHNIC DIFFERENCE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PRIORITY JOURNAL;

ADENOMATOUS POLYPS; COLONIC POLYPS; COLONOSCOPY; FEMALE; HUMANS; MALE; MIDDLE AGED; PROTON PUMP INHIBITORS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 34548680296     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2007.03450.x     Document Type: Article

References (87)

1. Larsson H, Carlsson E, Mattsson H, et al. Plasma gastrin and gastric enterochromaffinlike cell activation and proliferation. Studies with omeprazole and ranitidine in intact and antrectomized rats. Gastroenterology 1986 90 : 391 9.
2. Havu N. Enterochromaffin-like cell carcinoids of gastric mucosa in rats after life-long inhibition of gastric secretion. Digestion 1986 35 (Suppl. 10 42 55.
3. Larsson H, Hakanson R, Mattsson H, Ryberg B, Sundler F, Carlsson E. Omeprazole: its influence on gastric acid secretion, gastrin and ECL cells. Toxicol Pathol 1988 16 : 267 72.
4. Carlsson E, Havu N, Mattsson H, Ekman L. Gastrin and gastric enterochromaffin-like cell carcinoids in the rat. Digestion 1990 47 (Suppl. 1 17 23 49 52.
5. Ryberg B, Tielemans Y, Axelson J, et al. Gastrin stimulates the self-replication rate of enterochromaffinlike cells in the rat stomach. Effects of omeprazole, ranitidine, and gastrin-17 in intact and antrectomized rats. Gastroenterology 1990 99 : 935 42.
6. Creutzfeldt W, Lamberts R. Is hypergastrinaemia dangerous to man? Scand J Gastroenterol Suppl 1991 180 : 179 91.
7. Solcia E, Fiocca R, Havu N, Dalvag A, Carlsson R. Gastric endocrine cells and gastritis in patients receiving long-term omeprazole treatment. Digestion 1992 51 (Suppl. 1 82 92.
8. Lamberts R, Creutzfeldt W, Struber HG, Brunner G, Solcia E. Long-term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth, and gastritis. Gastroenterology 1993 104 : 1356 70.
9. Klinkenberg-Knol EC, Festen HP, Jansen JB, et al. Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med 1994 121 : 161 7.
10. Kuipers EJ, Lundell L, Klinkenberg-Knol EC, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 1996 334 : 1018 22.
11. Eissele R, Brunner G, Simon B, Solcia E, Arnold R. Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia. Gastroenterology 1997 112 : 707 17.
12. Sobhani I, Lehy T, Laurent-Puig P, Cadiot G, Ruszniewski P, Mignon M. Chronic endogenous hypergastrinemia in humans: evidence for a mitogenic effect on the colonic mucosa. Gastroenterology 1993 105 : 22 30.
13. Koh TJ, Goldenring JR, Ito S, et al. Gastrin deficiency results in altered gastric differentiation and decreased colonic proliferation in mice. Gastroenterology 1997 113 : 1015 25.
14. Renga M, Brandi G, Paganelli GM, et al. Rectal cell proliferation and colon cancer risk in patients with hypergastrinaemia. Gut 1997 41 : 330 2.
15. Winsett OE, Townsend CM, Glass EJ, Thompson JC. Gastrin stimulates growth of colon cancer. Surgery 1986 99 : 302 7.
16. Watson S, Durrant L, Morris D. Gastrin: growth enhancing effects on human gastric and colonic tumour cells. Br J Cancer 1989 59 : 554 8.
17. Johnson LR, Lichtenberger LM, Copeland EM, Dudrick SJ, Castro GA. Action of gastrin on gastrointestinal structure and function. Gastroenterology 1975 68 : 1184 92.
18. Dembinski AB, Johnson LR. Growth of pancreas and gastrointestinal mucosa in antrectomized and gastrin-treated rats. Endocrinology 1979 105 : 769 73.
19. Mak KM, Chang WW. Pentagastrin stimulates epithelial cell proliferation in duodenal and colonic crypts in fasted rats. Gastroenterology 1976 71 : 1117 20.
20. Hakanson R, Blom H, Carlsson E, Larsson H, Ryberg B, Sundler F. Hypergastrinaemia produces trophic effects in stomach but not in pancreas and intestines. Regul Pept 1986 13 : 225 33.
21. Graffner H, Singh G, Chaudry I, Milsom JW. Omeprazole induced hypergastrinemia does not influence growth of colon carcinoma. Dig Dis Sci 1992 37 : 485 9.
22. Pinson DM, Havu N, Sztern MI, et al. Drug-induced hypergastrinemia: absence of trophic effects on colonic carcinoma in rats. Gastroenterology 1995 108 : 1068 74.
23. Hurwitz A, Sztern MI, Looney GA, Pinson DM, Bauer KD, Kimler BF. Effects of omeprazole on cell kinetics of carcinogen-induced colon tumours in rats. Cell Prolif 1995 28 : 525 31.
24. Penman ID, El-Omar E, McGregor JR, Hillan KJ, O'Dwyer PJ, McColl KE. Omeprazole inhibits colorectal carcinogenesis induced by azoxymethane in rats. Gut 1993 34 : 1559 65.
25. McGregor DB, Jones RD, Karlin DA, Romsdahl MM. Trophic effects of gastrin on colorectal neoplasms in the rat. Ann Surg 1982 195 : 219 23.
26. Karlin DA, McBath M, Jones RD, Elwyn KE, Romsdahl MM. Hypergastrinemia and colorectal carcinogenesis in the rat. Cancer Lett 1985 29 : 73 8.
27. Smith JP, Wood JG, Solomon TE. Elevated gastrin levels in patients with colon cancer or adenomatous polyps. Dig Dis Sci 1989 34 : 171 4.
28. Seitz JF, Giovannini M, Gouvernet J, Gauthier AP. Elevated serum gastrin levels in patients with colorectal neoplasia. J Clin Gastroenterol 1991 13 : 541 5.
29. Wong K, Beardshall K, Waters CM, Calam J, Poston GJ. Postprandial hypergastrinaemia in patients with colorectal cancer. Gut 1991 32 : 1352 4.
30. Charnley RM, Thomas WM, Stanley J, Morris DL. Serum gastrin concentrations in colorectal cancer patients. Ann R Coll Surg Engl 1992 74 : 138 41.
31. Suzuki H, Matsumoto K, Terashima H. Serum levels of gastrin in patients with colorectal neoplasia. Dis Colon Rectum 1988 31 : 716 7.
32. Kikendall JW, Glass AR, Sobin LH, Bowen PE. Serum gastrin is not higher in subjects with colonic neoplasia. Am J Gastroenterol 1992 87 : 1394 7.
33. Yapp R, Modlin IM, Kumar RR, Binder HJ, Dubrow R. Gastrin and colorectal cancer. Evidence against an association. Dig Dis Sci 1992 37 : 481 4.
34. Penman ID, El-Omar E, Ardill JE, et al. Plasma gastrin concentrations are normal in patients with colorectal neoplasia and unaltered following tumor resection. Gastroenterology 1994 106 : 1263 70.
35. Vanderstraeten EF, De Vos MM, Versieck JM, Elewaut AP. Serum gastrin levels and colorectal neoplasia. Dis Colon Rectum 1995 38 : 172 6.
36. Fontanesi BV, Boris B, Delcio M, Manoukian FN. Gastrin levels in patients with colorectal cancer. Hepatogastroenterology 1997 44 : 1082 4.
37. Maton PN. Omeprazole. N Engl J Med 1991 324 : 965 75.
38. Bateson MC. Hypergastrinaemia with long-term omeprazole treatment. Aliment Pharmacol Ther 1999 13 : 440 1.
39. McCloy RF. Implications of a review of long-term safety of omeprazole and management strategies for peptic disease. Hepatogastroenterology 1992 39 : 90 1.
40. Thorburn CM, Friedman GD, Dickinson CJ, Vogelman JH, Orentreich N, Parsonnet J. Gastrin and colorectal cancer: a prospective study. Gastroenterology 1998 115 : 275 80.
41. Koh TJ, Chen D. Gastrin as a growth factor in the gastrointestinal tract. Regul Pept 2000 93 : 37 44.
42. Ciccotosto GD, McLeish A, Hardy KJ, Shulkes A. Expression, processing, and secretion of gastrin in patients with colorectal carcinoma. Gastroenterology 1995 109 : 1142 53.
43. Stepan VM, Sawada M, Todisco A, Dickinson CJ. Glycine-extended gastrin exerts growth-promoting effects on human colon cancer cells. Mol Med 1999 5 : 147 59.
44. Kermorgant S, Lehy T. Glycine-extended gastrin promotes the invasiveness of human colon cancer cells. Biochem Biophys Res Commun 2001 285 : 136 41.
45. Baldwin GS, Shulkes A. Gastrin receptors and colorectal carcinoma. Gut 1998 42 : 581 4.
46. el-Zimaity HM, Jackson FW, Graham DY. Fundic gland polyps developing during omeprazole therapy. Am J Gastroenterol 1997 92 : 1858 60.
47. Choudhry U, Boyce HW, Coppola D. Proton pump inhibitor-associated gastric polyps: a retrospective analysis of their frequency, and endoscopic, histologic, and ultrastructural characteristics. Am J Clin Pathol 1998 110 : 615 21.
48. Jalving M, Koornstra JJ, Wesseling J, Boezen HM, de Jong S, Kleibeuker JH. Increased risk of fundic gland polyps during long-term proton pump inhibitor therapy. Aliment Pharmacol Ther 2006 1 : 24.
49. Malecka-Panas E, Fligiel SE, Jaszewski R, Majumdar AP. Differential responsiveness of proximal and distal colonic mucosa to gastrin. Peptides 1997 18 : 559 65.
50. Georgopoulos SD, Polymeros D, Triantafyllou K, et al. Hypergastrinemia is associated with increased risk of distal colon adenomas. Digestion 2006 74 : 42 6.
51. American Cancer Society. Cancer Facts and Figures: Special Edition 2005. Atlanta : American Cancer Society 2005. Available at: http://www.cancer.org/ downloads/STT/CAFF2005CR4PWSecured.pdf.
52. Aickin M, Alberts DS. The measurement of adenoma occurrence. Eur J Cancer Prev 1996 5 : 43 8.
53. Lieberman DA, Weiss DG, Bond JH, Ahnen DJ, Garewal H, Chejfec G. Use of colonoscopy to screen asymptomatic adults for colorectal cancer. Veterans Affairs Cooperative Study Group 380. N Engl J Med 2000 343 : 162 8.
54. Tobi M, Chintalapani S, Goo R, et al. Omeprazole inhibits growth of cancer cell line of colonic origin. Dig Dis Sci 1995 40 : 1526 30.
55. Jass JR. Hyperplastic polyps of the colorectum-innocent or guilty? Dis Colon Rectum 2001 44 : 163 6.
56. Jass JR. Hyperplastic polyps and colorectal cancer: is there a link? Clin Gastroenterol Hepatol 2004 2 : 1 8.
57. Bardhan KD, Cherian P, Bishop AE, et al. Pantoprazole therapy in the long-term management of severe acid peptic disease: clinical efficacy, safety, serum gastrin, gastric histology, and endocrine cell studies. Am J Gastroenterol 2001 96 : 1767 76.
58. Ligumsky M, Lysy J, Siguencia G, Friedlander Y. Effect of long-term, continuous versus alternate-day omeprazole therapy on serum gastrin in patients treated for reflux esophagitis. J Clin Gastroenterol 2001 33 : 32 5.
59. Moller H, Lindvig K, Klefter R, Mosbech J, Moller Jensen O. Cancer occurrence in a cohort of patients treated with cimetidine. Gut 1989 30 : 1558 62.
60. Laine L, Ahnen D, McClain C, Solcia E, Walsh JH. Review article: potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther 2000 14 : 651 68.
61. el-Nujumi A, Williams C, Ardill JE, Oien K, McColl KE. Eradicating Helicobacter pylori reduces hypergastrinaemia during long-term omeprazole treatment. Gut 1998 42 : 159 65.
62. Gurbuz AK, Kucukkardali Y, Yazgan Y, Ozel M, Polat T. Does eradication of Helicobacter pylori infection reduce hypergastrinema during long term therapy with proton pump inhibitors? Turk J Gastroenterol. 2002 13 : 159 63.
63. Meucci G, Tatarella M, Vecchi M, et al. High prevalence of Helicobacter pylori infection in patients with colonic adenomas and carcinomas. J Clin Gastroenterol 1997 25 : 605 7.
64. Breuer-Katschinski B, Nemes K, Marr A, et al. Helicobacter pylori and the risk of colonic adenomas. Colorectal Adenoma Study Group. Digestion 1999 60 : 210 5.
65. Mizuno S, Morita Y, Inui T, et al. Helicobacter pylori infection is associated with colon adenomatous polyps detected by high-resolution colonoscopy. Int J Cancer 2005 117 : 1058 9.
66. Kune G, Watson L. Colorectal cancer protective effects and the dietary micronutrients folate, methionine, vitamins B6, B12, C, E, selenium, and lycopene. Nutr Cancer 2006 56 : 11 21.
67. Harnack L, Jacobs DR, Nicodemus K, Lazovich D, Anderson K, Folsom AR. Relationship of folate, vitamin B-6, vitamin B-12, and methionine intake to incidence of 'colorectal cancers. Nutr Cancer 2002 43 : 152 8.
68. Otani T, Iwasaki M, Hanaoka T, et al. Folate, vitamin B6, vitamin B12, and vitamin B2 intake, genetic polymorphisms of related enzymes, and risk of colorectal cancer in a hospital-based case-control study in Japan. Nutr Cancer 2005 53 : 42 50.
69. Hartman TJ, Albert PS, Snyder K, et al. The association of calcium and vitamin D with risk of colorectal adenomas. J Nutr 2005 135 : 252 9.
70. Kearney J, Giovannucci E, Rimm EB, et al. Calcium, vitamin D, and dairy foods and the occurrence of colon cancer in men. Am J Epidemiol 1996 143 : 907 17.
71. Sun CL, Yuan JM, Koh WP, Yu MC. Green tea, black tea and colorectal cancer risk: a meta-analysis of epidemiologic studies. Carcinogenesis 2006 27 : 1301 9.
72. Kawamori T, Lubet R, Steele VE, et al. Chemopreventive effect of curcumin, a naturally occurring anti-inflammatory agent, during the promotion/progression stages of colon cancer. Cancer Res 1999 59 : 597 601.
73. Cruz-Correa M, Shoskes DA, Sanchez P, et al. Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis. Clin Gastroenterol Hepatol 2006 4 : 1035 8.
74. Poynter JN, Gruber SB, Higgins PD, et al. Statins and the risk of colorectal cancer. N Engl J Med 2005 352 : 2184 92.
75. Friis S, Poulsen AH, Johnsen SP, et al. Cancer risk among statin users: a population-based cohort study. Int J Cancer 2005 114 : 643 7.
76. Coogan PF, Smith J, Rosenberg L. Statin use and risk of colorectal cancer. J Natl Cancer Inst 2007 99 : 32 40.
77. Moorman PG, Hamilton RJ. Statins and cancer risk: what do we know and where do we go from here? Epidemiology 2007 18 : 194 6.
78. Jacobs EJ, Rodriguez C, Brady KA, Connell CJ, Thun MJ, Calle EE. Cholesterol-lowering drugs and colorectal cancer incidence in a large United States cohort. J Natl Cancer Inst 2006 98 : 69 72.
79. Clevers H. Colon cancer-understanding how NSAIDs work. N Engl J Med 2006 354 : 761 3.
80. Siersema PD, Yu S, Sahbaie P, et al. Colorectal neoplasia in veterans is associated with Barrett's esophagus but not with proton-pump inhibitor or aspirin/NSAID use. Gastrointest Endosc 2006 63 : 581 6.
81. Robertson DJ, Larsson H, Friss S, Baron JA, Sorensen HT. Proton pump inhibitor use and risk of colorectal cancer: a population based case control study. Am J of Gastroenterol 101, S2, S216, 2006 (Abstract).
82. Dent J, Yeomans ND, Mackinnon M, et al. Omeprazole v ranitidine for prevention of relapse in reflux oesophagitis. A controlled double blind trial of their efficacy and safety. Gut 1994 35 : 590 8.
83. Reilly JP. Safety profile of the proton-pump inhibitors. Am J Health Syst Pharm 1999 56 : S11 7.
84. Freston JW, Rose PA, Heller CA, Haber M, Jennings D. Safety profile of Lansoprazole: the US clinical trial experience. Drug Saf 1999 20 : 195 205.
85. Lind T, Cederberg C, Forssell H, Olausson M, Olbe L. Relationship between reduction of gastric acid secretion and plasma gastrin concentration during omeprazole treatment. Scand J Gastroenterol 1988 23 : 1259 66.
86. Havu N. Gastric morphology during long-term omeprazole therapy. Gastroenterology 1998 114 : A145.
87. Koop H, Arnold R. Long-term maintenance treatment of reflux esophagitis with omeprazole. Prospective study in patients with H2-blocker-resistant esophagitis. Dig Dis Sci 1991 36 : 552 7.